Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy

NCT00957918 is registered in ClinicalTrials.gov with Neuraltus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00957918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00957918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2009
Completion date
September 30, 2010
Enrollment
65 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease